Sarcoma (Soft Tissue Sarcoma)

A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.

Also Known As:

Soft Tissue Sarcoma; Sarcomas; Soft Tissue Sarcomas; Spindle Cell Sarcoma; Epithelioid Sarcoma; Epithelioid Sarcomas; Sarcomas, Epithelioid; Sarcomas, Soft Tissue; Sarcomas, Spindle Cell; Spindle Cell Sarcomas; Sarcoma, Epithelioid; Sarcoma, Soft Tissue; Sarcoma, Spindle Cell

Networked: 23140 relevant articles (1251 outcomes, 3409 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Sarcoma (Soft Tissue Sarcoma)
3.	Neoplasm Metastasis (Metastasis)
4.	Melanoma (Melanoma, Malignant)
5.	Carcinoma (Carcinomatosis)

Experts

1.	Blay, Jean-Yves: 145 articles (01/2022 - 01/2003)
2.	Jones, Robin L: 102 articles (03/2022 - 07/2007)
3.	Gronchi, Alessandro: 95 articles (07/2022 - 08/2004)
4.	Le Cesne, Axel: 92 articles (01/2022 - 08/2005)
5.	Maki, Robert G: 76 articles (01/2022 - 08/2002)
6.	Italiano, Antoine: 74 articles (01/2022 - 05/2010)
7.	Kirsch, David G: 67 articles (07/2022 - 04/2007)
8.	Kawai, Akira: 66 articles (05/2022 - 04/2002)
9.	Antonescu, Cristina R: 64 articles (09/2022 - 08/2002)
10.	Pollock, Raphael E: 60 articles (02/2022 - 04/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Sarcoma:

1.	Doxorubicin (Adriamycin)FDA LinkGeneric 10/01/2017 - "Doxorubicin should remain the standard first-line treatment for most patients with advanced soft-tissue sarcoma. " 01/01/2017 - "Given the very limited efficacy of doxorubicin (doxo) in soft tissue sarcoma, there is a clear need for more active and less toxic treatments for this family of diseases. " 06/08/2022 - "Bone sarcomas have not shown a significant improvement in survival for decades, due, in part, to the development of resistance to current systemic treatments, such as doxorubicin. " 01/01/2013 - "Doxorubicin, first reported to have activity in sarcomas 40 years ago, remains the generalizable first-line treatment of choice for many subtypes, with no other drug or combination having shown an overall-survival advantage. " 11/01/2020 - "Although multiple trials have attempted to show improved outcomes in patients with soft-tissue sarcoma over doxorubicin monotherapy, each has fallen short of demonstrating improved outcomes. "
2.	Ifosfamide FDA LinkGeneric 10/18/2023 - "In this prospective, multicenter, one-stage, single-arm phase II trial, we assessed the combination of NPLD and ifosfamide as first-line treatment for advanced/metastatic soft tissue sarcoma (STS). " 08/01/2000 - "Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma." 01/01/2015 - "This phase II trial was performed to evaluate the activity and the safety of NPLD and ifosfamide combination in patients with metastatic soft tissue sarcoma. " 07/01/2011 - "The aim of present study was to determine the frequency and severity of ifosfamide nephropathy in patients with various types of sarcoma. " 03/01/2006 - "Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas."
3.	TrabectedinIBA 06/01/2012 - "Previous studies in sarcoma found that a composite gene signature, including high expression of nucleotide excision repair (NER) genes (XPG and/or ERCC1) and low expression of homologous recombination repair (HR) genes (BRCA1), identifies a highly sensitive population of patients with significantly improved outcome to trabectedin. " 01/01/2013 - "The present paper on a promising treatment with neoadjuvant trabectedin of patients with high-grade pleomorphic sarcoma might suggest that such treatment approach may provide a greater chance of cure and survival of such patients." 01/01/2013 - "This polymorphism was previously shown to be associated with better outcome in soft tissue sarcoma patients treated with trabectedin. " 01/01/2016 - "Trabectedin is reported to be particularly effective against translocation-related sarcoma. " 08/01/2014 - "Trabectedin may be especially effective against translocation-related sarcomas."
4.	pazopanib FDA Link 01/01/2020 - "Conclusions: The VIPaz regimen might be a safe option in children and adolescents with relapsed or refractory sarcomas otherwise unable to be enrolled in other clinical trials; on the other hand, the efficacy of pazopanib observed cannot be sustained from the current study." 01/11/2019 - "Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation." 01/01/2016 - "Pazopanib is effective in soft tissue sarcomas but has never been assessed in advanced GIST in a randomised trial. " 04/01/2021 - "This study evaluated the safety and efficacy of pazopanib in patients with metastatic soft tissue sarcoma in routine clinical use in Japan. " 11/01/2019 - "In the present study we aimed to evaluate the efficacy of pazopanib in metastatic uterine sarcoma. "
5.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/01/2009 - "The objective of the present study was to confirm these data on a larger sample size of locally advanced or recurrent extremity soft tissue sarcomas with low-dose TNF-alpha. " 08/01/1992 - "In this study, we investigated the effect of tumor necrosis factor-alpha (TNF alpha) on the generation and function of IVS cells utilized in adoptive immunotherapy of the murine MCA 106 sarcoma. " 01/01/2018 - "In contrast, localized administration of TNF-alpha in the form of isolated limb perfusion have yielded excellent results in soft tissue sarcomas. " 03/01/2009 - "Tumor necrosis factor-alpha (TNFalpha)-based hyperthermic isolated limb perfusion (HILP) is routinely carried out at most oncological institutions in the treatment of locally advanced soft tissue limb sarcoma (STS), employing high TNFalpha dosages. " 12/01/2007 - "The addition of tumor necrosis factor-alpha (TNF-alpha) to this treatment approach contributed to a major step forward in the treatment of locally advanced extremity soft tissue sarcoma (STS). "
6.	AnthracyclinesIBA 07/05/2021 - "We investigated if molecular alterations identified in these trials in sarcomas were associated with disease-free survival (DFS) and response to anthracyclines. " 01/01/2020 - "Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study." 07/30/2016 - "For both the phase 1b and phase 2 parts of the study, eligible patients were aged 18 years or older and had a histologically confirmed diagnosis of locally advanced or metastatic soft-tissue sarcoma not previously treated with an anthracycline, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and available tumour tissue to determine PDGFRα expression by immunohistochemistry. " 08/01/2013 - "The occurrence of secondary sarcomas, in the Children's Cancer Survivor study conducted in North America, has been associated with high cumulative doses of anthracyclines, which may also have played a role in the development of RMS in the present case. " 01/01/2023 - "Our findings demonstrate feasibility of LS in a majority of echocardiograms and a high incidence of impaired LS during anthracycline treatment for childhood sarcoma. "
7.	Melphalan (Alkeran)FDA LinkGeneric 03/15/1997 - "The combination of high dose rTNF-alpha and melphalan given via ILP appears to be effective in patients with advanced soft tissue sarcoma confined to the limb, achieving a high response rate and limb preservation." 05/01/2001 - "HILP with melphalan is a safe and effective treatment option for selected patients with locally advanced and unresectable extremity sarcomas. " 03/15/1997 - "The purpose of the current study was to assess the role of rTNF-alpha and melphalan administered via ILP in patients with soft tissue sarcoma. " 01/01/2019 - "Hyperthermic isolated limb perfusion with tasonermin and melphalan is an important part of a multimodal approach in the treatment of extremity sarcomas with a high percentage of responses that increase the percentage of limbs retaining resections. " 01/01/2019 - " Design: In an established animal model of extremity sarcoma, we evaluated the potential of locoregional delivery of a vaccinia virus (GLV-1h68) alongside biochemotherapy (melphalan/TNFα) in ILP. "
8.	Gemcitabine FDA Link 01/01/2018 - "Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models." 02/01/2016 - "Because of conflicting results from successive non-randomized phase II trials, gemcitabine activity alone in unselected pretreated soft tissue sarcomas could not be properly assessed. " 02/01/2016 - "We have systematically reviewed all of the fully published trials that investigated a gemcitabine-based regimen in the management of sarcomas and then provided a grade of recommendations and a level of evidence for every recommendation. " 12/01/2008 - "Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study." 05/01/2007 - "This study contributed to data that have supported the administration of fixed-dose rate gemcitabine-based drug regimens in soft-tissue sarcomas."
9.	Proteins (Proteins, Gene)FDA Link 09/01/1987 - "Whole-body protein turnover rates were significantly greater in sarcoma patients than age-matched controls (15%). " 01/01/2021 - "Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas." 06/01/2013 - "The blood samples were heat-treated, in which we supposed mainly MT, but samples contained other thermostable Zn-containing proteins that were helpful for identification of embryonal tumours with 88% accuracy and for identification of sarcomas with 78% accuracy. " 01/01/2022 - "In this study, to elucidate how the recruitment and diffusion properties of guest proteins are affected by a host protein, we characterized the properties of guest proteins in fused in sarcoma (FUS) droplets using single-molecule fluorescence microscopy in comparison with p53 droplets. " 12/01/2019 - "We characterize the effects of varying macroscale and microscale stiffnesses in 3D environments on the localization and expression of the mechanoresponsive proteins, YAP and TAZ, and evaluate IGF-1R/mTOR pathway activation, a target of recent clinical trials in sarcoma. "
10.	Cisplatin (Platino)FDA LinkGeneric 07/01/2005 - "The objectives of this study were to investigate the pharmacokinetics of cisplatin (CDDP) and the thermal dose, toxicity, and feasibility of hyperthermic isolated regional perfusion (HIRP) with CDDP for bone and soft-tissue sarcomas of the lower limb. " 07/01/1986 - "The M5076 sarcoma was used to evaluate the antitumor activities of several analogs of Platinol presently undergoing clinical trials. " 02/01/1986 - "Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study." 11/15/1982 - "Phase II trial of cisplatin (CPDD) in previously treated patients with advanced soft tissue sarcoma." 11/01/1979 - "Cis-dichlorodiammineplatinum(II) in advanced soft tissue and bony sarcomas: a Southwest Oncology Group Study."

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 07/15/2019 - "While multiagent chemotherapy has dramatically improved the prognosis of sarcoma, the novel chemotherapeutics have hardly developed over the past 30 years. " 01/01/2018 - "The historically recent advent of cytotoxic chemotherapy for pediatric sarcomas has revolutionized the treatment of these diseases and dramatically improved their prognoses. " 01/01/2018 - "Over the last few decades, traditional treatment with surgery and/or chemotherapy has not significantly improved outcomes for most types of sarcomas. " 01/01/2017 - "The best treatment for sarcomas in case of organ-confined disease and in selected cases of locally advanced disease seems to be surgery followed by chemotherapy. " 09/01/2014 - "There are limited data to guide the best treatment for radiation-associated sarcoma, therefore, the standard chemotherapy options are reasonable choices. "
2.	Therapeutics 08/19/2021 - "Since the outcome for most sarcoma patients has barely improved in the last decades, there is an urgent need for improved therapies. " 11/03/2014 - "RMS is the most common pediatric soft-tissue sarcoma, and approximately 60% of all children and adolescents diagnosed with RMS are cured by currently available multimodal therapies. " 07/01/1985 - "The combined therapy of LAK cells plus RIL 2 was shown to be highly effective in mice immunosuppressed by 500 rad total body irradiation and in treating macrometastases established in the lung 10 days after the i.v. injection of sarcoma cells. " 07/01/2009 - "The use of multimodality therapy has resulted in markedly improved cure rates for patients with sarcomas in the past 25 years. " 01/01/1996 - "We suggest that these improved local treatments should be combined with aggressive systemic therapy in order to develop an optimal adjuvant approach to the treatment of sarcoma. "
3.	Radiotherapy 01/01/1998 - "This study indicates that although postoperative external-beam radiotherapy is highly effective in preventing LRs, selected patients with extremity soft tissue sarcoma who have a low risk of LR may not require adjuvant XRT after limb-sparing surgery (LSS)." 08/01/1996 - "The best treatment for thyroid sarcomas and SCC of the thyroid is early diagnosis and aggressive surgery combined with radiotherapy." 01/06/2016 - "For resectable soft tissue sarcoma (STS), radical surgery, usually combined with radiotherapy, is the mainstay of treatment and the only potentially curative modality. " 05/01/2014 - "Also preoperative radiation therapy has proven to be effective in controlling locally advanced sarcoma despite higher perioperative morbidity which pays off in the long run by better limb function. " 02/01/2011 - "The gold standard for the treatment of primary, resectable, high-grade soft tissue sarcomas is complete surgical removal followed by radiotherapy. "
4.	Immunotherapy 06/05/2020 - "Recent immunotherapy studies with PD1 inhibitors (PD1i) show promising results with use in certain soft-tissue sarcomas; however, the clinical and molecular features that best predict response to PD1i remain unclear. " 11/17/2023 - "Immunotherapy has not been shown to be effective for most patients with sarcoma, including those with LMS. " 07/01/2023 - "Anti-PD1-based immunotherapy is highly efficacious in advanced sarcomas of cutaneous primary site. " 01/01/2011 - "While past attempts to use immunotherapy have failed to dramatically shift the paradigm of care for the treatment of patients with sarcoma, major advances in basic and translational research have resulted, in more recent years, in clinical trial activity that is now beginning to generate promising results. " 01/01/2022 - "However, in patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, the superior efficacy of immunotherapy has not been elucidated and especially in real-world practice. "
5.	Adjuvant Chemotherapy 11/01/2000 - "Both studies confirm the advantage of adjuvant chemotherapy in disease-free and overall surivall in very select groups of high-grade sarcomas of the extremities." 01/01/2020 - "In the randomized controlled trial (RCT) EORTC 62931, adjuvant chemotherapy failed to show improvement in relapse-free survival (RFS) or overall survival (OS) for patients with resected high-grade soft tissue sarcoma (STS). " 06/01/1998 - "Adjuvant chemotherapy has significantly improved the prognosis of patients with bone sarcomas. " 04/15/1986 - "These results suggest that primary adjuvant chemotherapy is beneficial in patients with Stage I uterine sarcomas." 03/15/1985 - "Since 1977, 31 patients were entered in a randomized, prospective study testing the efficacy of adjuvant chemotherapy after aggressive local treatment of high-grade sarcomas of the head, neck, breast, and trunk (excluding retroperitoneal sarcomas). "